我要投票 美宝Mebo在医疗器械行业中的票数:174
· 外 推 电 报 ·
2025-01-18 20:21:53 星期六

【美宝Mebo是哪个国家的品牌?】

美宝Mebo是什么牌子?「美宝Mebo」是 美宝医药科技集团有限公司 旗下著名品牌。该品牌发源于广东省汕头市,由创始人杨智斌在1990-08-06期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

成立于1987年,伤药知名品牌,其湿润烧伤膏为原位皮肤再生治疗烧伤的知名药品,主要从事烧伤、创疡、皮肤再生医药医疗的企业


美宝集团,是惠及世界的新生命科学企业集团,拥有丰富的世界化的知识产权财富,是世界烧伤创疡再生医疗技术MEBO/MEBT奠基地,是实现美国总统“发展药物使损伤器官再生”国策的经济领航体,是再生生命产业链引擎,是人类进入再生生命新经济世界的引导型企业。

美宝集团成立于1987年,前身是徐荣祥医生和李俐医生创建的北京光明中医烧伤创疡研究所。1988年,徐荣祥发明的湿润烧伤膏获得中国卫生部新药证书,成为1984年中国《药品管理法》实施后被批准的中药新药。该药物与烧伤湿润暴露疗法(MEBT/MEBO)是八五规划中卫生部向全国推广普及的十项医药技术之一。

美宝集团在中国、美国分设两个总部,拥有美国、中国、泰国、印度、马来西亚等多家跨国的烧伤、创疡、皮肤再生医药医疗企业,拥有具有自主知识产权的药品、保健品、营养食品、美容护肤产品、医疗器械等几十余种系列再生产品。在70多个国家,有20多万医生在20多个领域使用美宝的技术及产品,治愈了4000多万烧伤创疡患者,实现了大面积深度烧伤、糖尿病溃疡、末节断指、开放缺损型创伤、下肢溃疡、深度褥疮等损伤器官的原位再生复原。

美宝集团拥有40多项中、美、欧、日等国家和地区的国际发明专利,包括潜能再生细胞及其培养方法、通过体内和原位进行干细胞的培养来修复再生生理性的组织和功能性的器官等核心器官再生专利。美宝创始人徐荣祥所著《人体再生复原科学》、《烧伤再生医学与疗法》、《烧伤医疗技术蓝皮书》及《烧伤治疗大全》均被美国国家医学图书馆收录;而由瑞士Karger出版社出版的英文版《烧伤再生医学与疗法》(Burns Regenerative Medicine and Therapy)一书被哈佛大学、普林斯顿大学、麻省理工学院等十几所大学收藏。

美宝拥有国际化的基础和临床研究中心,有北京美宝烧伤创疡研究所、北京荣祥再生医学研究所,美国临床研究中心等多处研究基地。在创始人徐荣祥医生过世后,新任董事局主席徐鹏带领美宝拓展了一系列国际科研、企业与社会平台:加入了克林顿全球倡议并实施了惠及20,000名中国医生的美宝倡议“再生医疗技术医师培训”;加入了联合国“每个妇女、每个儿童”中国合作伙伴网络;与美国洛杉矶郡卫生局合作在洛杉矶卫生系统筹划“再生医疗技术培训”;在哈佛大学医学院合作建立了“徐荣祥再生治疗中心”;在南加州大学戴维斯老年学院合作成立了“徐荣祥再生生命科学中心”;冠名成立了洛杉矶州大“徐荣祥健康与公众服务大学”及“徐荣祥生物科学创新中心”等。美宝开始多方面多层次开展国际合作,进行人体损伤器官的再生复原研究、临床推广应用以及再生科学人才与社会领袖的培养。与此同时,还发起了美国徐荣祥基金会,中国红基会徐荣祥再生生命公益基金,通过另一种渠道在维护国际健康事务中积极发挥重要作用。

美宝不仅是一个公司,更是一个”为人类生命奋斗“的使命型企业,是一个为人类造福的科学技术集群。创始人徐荣祥在世界烧伤治疗领域和再生科学领域对人类社会做出了历史性贡献,为人类损伤器官再生的广泛临床应用奠定了坚实的基础,并为世界再生生命科学的发展提供了新的方向。


英文翻译:Founded in 1987, it is a well-known brand of wound medicine. Its MEBO is a well-known medicine for in-situ skin regeneration treatment. It is mainly engaged in burn, wound and skin regeneration medicine and medical treatment. It is a new life science enterprise group benefiting the world. It has rich world-wide intellectual property wealth. It is the foundation of MEBO / MEBT, a world burn regeneration medical technology The economic leader of the current US president's national policy of "developing drugs to regenerate damaged organs" is the engine of the industrial chain of renewable life and the leading enterprise for human beings to enter the new economic world of renewable life. Meibao group was founded in 1987, formerly known as Beijing Guangming burn and wound research institute founded by Dr. Xu Rongxiang and Dr. Li Li. In 1988, the MEBO invented by Xu Rongxiang obtained the new drug certificate issued by the Ministry of health of China and became a new Chinese medicine approved after the implementation of the drug administration law of China in 1984. MEBT / MEBO is one of the ten medical technologies popularized by the Ministry of health in the eighth five year plan. Meibao group has two headquarters in China and the United States. It has many multinational burn, wound and skin regeneration pharmaceutical and medical enterprises in the United States, China, Thailand, India, Malaysia, etc. it has more than ten series of renewable products, such as drugs, health products, nutritional food, beauty and skin care products, medical devices, etc. with independent intellectual property rights. In more than 70 countries, more than 200000 doctors have used Meibao's technology and products in more than 20 fields, cured more than 40 million patients with burns, wounds and ulcers, and realized in-situ regeneration and recovery of large-scale deep burns, diabetic ulcers, end segment severed fingers, open defect wounds, lower limb ulcers, deep bedsores and other damaged organs. Meibao group has more than 40 international invention patents in China, the United States, Europe, Japan and other countries and regions, including potential regenerative cells and their culture methods, core organ regeneration patents such as repairing physiological tissues and functional organs through stem cell culture in vivo and in situ. The science of human regeneration and recovery, burn regeneration medicine and therapy, blue book of burn medical technology and burn treatment encyclopedia, written by Xu Rongxiang, the founder of Meibao, are all included in the National Medical Library of the United States, while the English version of Burns Regenerative Medicine and therapy, published by Karger press in Switzerland, is published by Harvard University and general public Linton University, Massachusetts Institute of technology and more than a dozen universities. Meibao has international basic and clinical research centers, including Beijing Meibao burn and wound Research Institute, Beijing Rongxiang Regenerative Medicine Research Institute, American clinical research center and other research bases. After the death of Dr. Xu Rongxiang, the founder, Xu Peng, the new chairman of the board of directors, led Meibao to expand a series of international scientific research, enterprise and social platforms: joined the Clinton Global Initiative and implemented the benefit 20, MEBO initiative "training of regenerative medical technologists" of 000 Chinese doctors; joining the "every woman, every child" Chinese partner network of the United Nations; planning "regenerative medical technology training" in Los Angeles health system in cooperation with Los Angeles County Health Bureau of the United States; establishing "Xu Rongxiang regenerative treatment center" in Harvard University School of medicine; David, University of Southern California The Institute has established "Xu Rongxiang renewable Life Science Center" in cooperation, and "Xu Rongxiang health and public service university" and "Xu Rongxiang biological science innovation center" in Los Angeles State University. Meibao began to carry out international cooperation in various aspects and at various levels to carry out research on the regeneration and restoration of human damaged organs, clinical promotion and application, and training of regeneration science talents and social leaders. At the same time, it also launched the American Xu Rongxiang foundation and the Chinese Red foundation Xu Rongxiang renewable life public welfare fund, which play an important role in maintaining international health affairs through another channel. Meibao is not only a company, but also a mission enterprise "striving for human life". It is a scientific and technological cluster for the benefit of mankind. Xu Rongxiang, the founder, has made historic contributions to human society in the field of burn treatment and regeneration Science in the world, laying a solid foundation for the extensive clinical application of human organ regeneration, and providing a new direction for the development of world regeneration life science.

本文链接: https://www.waitui.com/brand/47c9dcac4.html 联系电话:01058701597

千城特选小程序码

7×24h 快讯

姚伟雄先生将不再担任安踏集团时尚运动品牌群 CEO 职务,江艳女士将接任时尚运动品牌群 CEO

36氪获悉,因已届退休年龄,姚伟雄先生将不再担任安踏集团时尚运动品牌群 CEO 职务,未来他将继续担任集团副总裁,负责集团时尚产业项目的日常管理与运营。自 2010 年起,姚伟雄先生一直负责 FILA品牌大中华地区的业务,带领团队将 FILA 打造成中国时尚运动赛道的标杆品牌,跻身中国前五大运动品牌之列。集团高度肯定姚伟雄先生为公司和行业所做出的杰出贡献,并祝愿他在新的岗位继续发挥更多的才能。 江艳女士将接任时尚运动品牌群 CEO,全面负责时尚运动品牌群的经营管理,继续推动 FILA 夯实“高端时尚运动品牌“的心智定位,实现品牌驱动的业务增长。江艳女士是集团长期培养的年轻梯队干部,拥有丰富的品牌管理经验,曾先后操盘 ANTA KIDS FILA FUSION 的品牌管理工作,实现了两个品牌在细分市场的领先心智。她将领导 FILA 进一步拓展在年轻人群中的影响力,为消费者创造更多的价值。

22分钟前

国新创投基金启航 首期规模100亿元

中国国新联合部分中央企业、地方国资1月18日在京共同举行国新创投基金合作签约仪式。国新创投基金出资合作单位有中国五矿、中国钢研、中国建材、中国有研、中国电气装备、杭州资本、兴湘集团等,首期规模100亿元,存续期15年,同时将启动杭州、湖南、西安等一批子基金,通过母子基金放大方式,围绕“国家所需、创新所要、基金所能”,坚持投早、投小、投长期、投硬科技,为科技强国建设和新质生产力培育贡献力量。(财联社)

22分钟前

新凤鸣入选首批国家工信部“卓越级智能工厂”

近日,新凤鸣集团“化纤全产业链协同智能工厂”入选国家“卓越级智能工厂(第一批)项目名单(共235家)”,是浙江省上榜的13家企业之一,也是化纤行业唯一上榜企业。(证券时报)

22分钟前

先锋集团将支付1.06亿美元以和解美国SEC指控

美国证券交易委员会(SEC)当地时间1月17日在一份新闻稿中指出,先锋集团(The Vanguard Group, Inc.)将支付1.0641亿美元,以和解有关其对资本利得分配和税收影响的误导性陈述的指控,这些误导性陈述影响了在应纳税账户中持有先锋投资者目标退休基金(Investor TRFs)的零售投资者。和解金额将分配给受影响的投资者。(财联社)

22分钟前

今年首家!千亿公募换帅

2025年开年,公募基金行业迎来今年首次基金公司换帅。1月18日,兴银基金发布基金行业高级管理人员变更公告,公告显示,易勇新任兴银基金总经理,同时,董事长吴若曼不再代为履行总经理职务。 Wind数据显示,截至2024年9月30日,兴银基金旗下公募产品数量54只,公募管理规模为1067.32亿元。根据银河证券数据显示,近二年固收排名40/129,近三年排名32/119,近五年排名9/93,在权益方面,兴银基金近两年排名进入前10%(12/124)。(券商中国)

22分钟前

本页详细列出关于伟思VISHEE的品牌信息,含品牌所属公司介绍,伟思VISHEE所处行业的品牌地位及优势。
咨询